PSY14 COST-EFFECTIVENESS (CE) EVALUATION OF THE USE OF RITUXIMAB-CHOP VS. CHOP SCHEMES FOR THE TREATMENT OF AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL) STAGES III AND IV- TREATMENT IMPACT OVER RELAPSE AND SURVIVAL, AT THE MEXICAN-NATIONAL CANCER ...
Nov 1, 2008, 00:00 AM
10.1016/S1098-3015(10)67065-9
https://www.valueinhealthjournal.com/article/S1098-3015(10)67065-9/fulltext
Section Title :
Section Order :
900
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)67065-9&doi=10.1016/S1098-3015(10)67065-9